The brief

Analyst view

• Formed 2020; public (RDW) since Jan 2021. 750 employees in 2024; 1,300 across US and Europe.
• PIL-01 (Nov 2023) with Eli Lilly proved microgravity grows better insulin crystals. PIL-02 expanded research.
• SpaceMD venture launched 2025 to commercialize space pharma manufacturing with ExesaLibero.

Technical approach

As reported

Microgravity advantage

Crystals grow larger and more uniform

Protein molecules arrange into larger, purer crystals without gravity-driven settling, enabling clearer drug target views and faster development.

PIL-BOX hardware

Experimental chamber on the ISS

PIL-BOX is installed inside Redwire's ADSEP on the ISS. Runs experiments 20+ days with environment control, returns samples for analysis.

SpaceMD commercialization

New venture for production scale

SpaceMD enables regular pharmaceutical manufacturing, not research-only. Revenue-sharing partnerships (e.g., ExesaLibero).